Patent intelligence · US
US 12358979
Antibodies that bind interleukin 13 and methods of use
Antibodies that bind interleukin 13 and methods of use
Patent details — US 12358979
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 15, 2025
- Expiration
- Jul 10, 2045
- Applicant
- Apogee Therapeutics, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K2039/505
Quick answer
US 12358979 (Antibodies that bind interleukin 13 and methods of use) is held by Apogee Therapeutics, Inc.. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Apogee Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505
More from Apogee Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
granted -
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8557800
Sphingosine kinase inhibitors
granted -
US 8063248
Sphingosine kinase inhibitors
granted -
US 7338961
Sphingosine kinase inhibitors
granted
Frequently asked questions
What is US patent 12358979?
US 12358979 (Antibodies that bind interleukin 13 and methods of use) is held by Apogee Therapeutics, Inc.. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12358979?
Apogee Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12358979 expire?
Our index shows an expiration date of Jul 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.